抵抗素的研究进展

抵抗素(resistin)是近年来发现的一个新脂肪细胞因子,最初在动物实验被用于联系肥胖、胰岛素抵抗和2型糖尿病.但随着进一步在人类实验的研究中发现,抵抗素能调节炎症反应而非胰岛素敏感性,研究发现抵抗素能促进炎症发生,炎症因子也能调节抵抗素的表达.动脉硬化是一种慢性亚临床性炎症,大量的体外研究提示抵抗素有可能作为一种促炎因子,通过激活内皮功能,诱导平滑肌增殖迁移,促巨噬细胞的脂质沉积,导致脂质代谢紊乱等途径,促进动脉粥样硬化的发生与发展.     

抵抗素的研究进展

抵抗素（resistin）是近年来发现的一个新脂肪细胞因子,最初在动物实验被用于联系肥胖、胰岛素抵抗和2型糖尿病。但随着进一步在人类实验的研究中发现,抵抗素能调节炎症反应而非胰岛素敏感性,研究发现抵抗素能促进炎症发生,炎症因子也能调节抵抗素的表达。动脉硬化是一种慢性亚临床性炎症,大量的体外研究提示抵抗素有可能作为一种促炎因子,通过激活内皮功能,诱导平滑肌增殖迁移,促巨噬细胞的脂质沉积,导致脂质代谢紊乱等途径,促进动脉粥样硬化的发生与发展。     

抵抗素与胰岛素抵抗

抵抗素是最近发现的一种主要由脂肪细胞分泌的激素,因有对抗胰岛素的作用而得名。它在肥胖和胰岛素抵抗时表达明显增加,所以,有学者认为抵抗素是联系肥胖和胰岛素抵抗的中介。但也有实验结果不支持这些观点。抵抗素的表达受胰岛素增敏剂、营养状态及抵抗素拮抗剂等调节。     

抵抗素在胰岛素抵抗中的作用研究进展

抵抗素是近年来新近发现的一种脂肪组织特异性分泌的细胞因子,与肥胖、胰岛素抵抗和2型糖尿病有着密切关系.众多研究表明,抵抗素通过影响机体糖脂代谢,诱导肝脏、脂肪及肌肉组织产生胰岛素抵抗.本文简要介绍抵抗素和肝脏的胰岛素抵抗,并进一步分析抵抗素对肝脏糖、脂代谢及肝细胞胰岛素信号转导三方面的调节,重点说明抵抗素在肝脏胰岛素抵抗的作用.     

抵抗素与肥胖和2型糖尿病

抵抗素（resistin）是近年来新发现的一个由脂肪组织特异表达分泌的细胞因子,其在前脂肪细胞分化过程中抑制脂肪生成。众多的研究显示抵抗素可诱导脂肪、肝脏及肌肉组织产生胰岛素抵抗,损伤机体的糖脂代谢功能。由于胰岛素抵抗在一些其他代谢性疾病及并发症如动脉粥样硬化及高血压发病机制中也发挥重要作用,提示抵抗素有可能介入了这些疾病的发病过程。本文简要介绍抵抗素的结构、分布及表达调控,并重点分析抵抗素在胰岛素抵抗中的作用。     

抵抗素与肥胖和2型糖尿病

抵抗素(resistin)是近年来新发现的一个由脂肪组织特异表达分泌的细胞因子,其在前脂肪细胞分化过程中抑制脂肪生成.众多的研究显示抵抗素可诱导脂肪、肝脏及肌肉组织产生胰岛素抵抗,损伤机体的糖脂代谢功能.由于胰岛素抵抗在一些其他代谢性疾病及并发症如动脉粥样硬化及高血压发病机制中也发挥重要作用,提示抵抗素有可能介入了这些疾病的发病过程.本文简要介绍抵抗素的结构、分布及表达调控,并重点分析抵抗素在胰岛素抵抗中的作用.     

抵抗素、Ⅱ型糖尿病和血管形成

抵抗素是近年来新发现的一个富舍半胱氨酸的多肽,由于具有拮抗胰岛素的作用而得名.在啮齿类动物中,抵抗素主要由脂肪细胞特异性表达和分泌.目前对抵抗素的研究已获得了重要突破与进展,其三维结构也得到了证实.它不仅是联系肥胖症和Ⅱ型糖尿痛的重要蛋白,而且具有多种生物学功能,如干扰肝细胞的糖原代谢、促进内皮细胞增殖迁移和血管生长、减少心梗面积等.本文主要介绍抵抗素的最新研究进展,以及抵抗素在Ⅱ型糖尿病和血管形成中的重要作用.     

血尿酸对2型糖尿病动脉粥样硬化的影响

2型糖尿病患者发生大血管并发症的主要病理基础为动脉粥样硬化,且发生早、进展快、预后差、死亡率高,其引发的心脑血管疾病是糖尿病患者致死致残的主要原因之一.血尿酸是动脉粥样硬化的危险因素,与代谢综合征的多种成分,如肥胖、血脂异常、糖尿病、高血压、冠心病、胰岛素抵抗等密切相关.本文阐述2型糖尿病患者动脉粥样硬化发生中血尿酸的作用机制.     

慢性炎症与动脉粥样硬化关系的研究进展

动脉粥样硬化(atherosclerosis,AS)的发病机制非常复杂,对其研究经历了一个半世纪,直到1999年Ross提出"动脉粥样硬化是一种炎症性疾病",各种炎症细胞和炎症因子参与动脉粥样硬化的发生和发展过程。已有众多的基础和临床研究都证实炎症在AS中的重要作用,但仍需要对AS发生发展的深入研究,使我们更准确认识和有效的防治AS。本文就近年来慢性炎症与动脉粥样硬化关系的研究进展作一综述。     

慢性炎症与动脉粥样硬化关系的研究进展

动脉粥样硬化（atherosclerosis,AS）的发病机制非常复杂,对其研究经历了一个半世纪,直到1999年Ross提出”动脉粥样硬化是一种炎症性疾病”,各种炎症细胞和炎症因子参与动脉粥样硬化的发生和发展过程。已有众多的基础和临床研究都证实炎症在AS中的重要作用,但仍需要对AS发生发展的深入研究,使我们更准确认识和有效的防治AS。本文就近年来慢性炎症与动脉粥样硬化关系的研究进展作一综述。     

Resistin may be an independent predictor of subclinical atherosclerosis formale smokers

To investigate whether resistin is associated with early atherosclerosis in male smokers. The present study consecutively enrolled 50 male smokers. Their serum resistin contents were detected with enzyme linked immunosorbent assay (ELISA), and subclinical atherosclerosis indices, including carotid inner middle thickness (IMT) and arterial elasticity indices (C1 and C2), were measured. The association between serum resistin levels and IMT, C1 and C2 were respectively evaluated with the Pearson’s correlation coefficient method. The results showed that the serum resistin level had a positive association with IMT (r?=?0.307, p?=?.030), but were both inversely associated with C1 (r?=??0.440, p?=?.001) and C2 (r?=??0.381, p?=?.006). These associations remained significant even after adjustment for cardiovascular confounders. In conclusion, serum resistin concentration was independently associated with early atherosclerosis in male smokers.     

Resistin

PURPOSE OF REVIEW: Resistin, a cysteine-rich 12.5 kDa polypeptide, is a recently discovered adipocytokine with a controversial history regarding its role in the pathogenesis of obesity-mediated insulin resistance and type 2 diabetes mellitus. Whilst current studies appear to re-affirm the role of resistin on glucose homeostasis in rodent systems, we are still unravelling the functionality of resistin in human biology in respect to glucose metabolism and insulin signalling. This review will summarize the current knowledge, put into context the developments to date and discuss the controversial points. RECENT FINDINGS: Current evidence appears to suggest that resistin is a pro-inflammatory cytokine. Thus, like many other adipocytokines, resistin may possess a dual role in contributing to metabolic disease: first through its direct effects on substrate metabolism and second, through regulating inflammation within its target tissues. The chemistry of resistin has also been the subject of investigation and like adiponectin, the homo-oligomerization of this protein has a bearing on its function. SUMMARY: The most recent advances include the identification of circulating higher molecular weight structures of resistin in both rodent and human serum. This has been complemented by work casting light on the function and purpose of multimeric resistin in mice. Resistin appears to have effects on substrate metabolism through impairment of insulin action, particularly in the liver, but in addition, also has effects on insulin independent pathways.     

Resistin worsens cardiac ischaemia-reperfusion injury

We provide the first report of direct effects of resistin upon haemodynamic and neurohumoral parameters in isolated perfused rat heart preparations. Pre-conditioning with 1 nmol L-1 recombinant human resistin prior to ischaemia significantly impaired contractile recovery during reperfusion, compared with vehicle-infused hearts (P<0.05, n=12). This was accompanied by a significant increase in both A-type and B-type natriuretic peptides (P<0.05, n=12 both ANP and BNP vs vehicle), creatine kinase, and tumour necrosis factor-alpha (TNF-alpha) release in resistin-infused hearts. Resistin had no significant effect on myocardial glucose uptake. Co-infusion of resistin with Bay 11 7082 (an NF-kappaB inhibitor) improved contractile recovery following ischaemia and reduced both natriuretic peptide and creatine kinase release. This is the first evidence indicating resistin impairs cardiac recovery following ischaemia, stimulates cardiac TNF-alpha secretion, and modulates reperfusion release of natriuretic peptides and biochemical markers of myocardial damage. A TNF-alpha signalling related mechanism is suggested as one component underlying these effects.     

Resistin in idiopathic inflammatory myopathies

Introduction

The purpose of this study was to evaluate and compare the serum levels and local expression of resistin in patients with idiopathic inflammatory myopathies to controls, and to determine the relationship between resistin levels, inflammation and disease activity.

Methods

Serum resistin levels were determined in 42 patients with inflammatory myopathies and 27 healthy controls. The association among resistin levels, inflammation, global disease activity and muscle strength was examined. The expression of resistin in muscle tissues from patients with inflammatory myopathies and healthy controls was evaluated. Gene expression and protein release from resistin-stimulated muscle and mononuclear cells were assessed.

Results

In patients with inflammatory myopathies, the serum levels of resistin were significantly higher than those observed in controls (8.53 ± 6.84 vs. 4.54 ± 1.08 ng/ml, P < 0.0001) and correlated with C-reactive protein (CRP) levels (r = 0.328, P = 0.044) and myositis disease activity assessment visual analogue scales (MYOACT) (r = 0.382, P = 0.026). Stronger association was observed between the levels of serum resistin and CRP levels (r = 0.717, P = 0.037) as well as MYOACT (r = 0.798, P = 0.007), and there was a trend towards correlation between serum resistin and myoglobin levels (r = 0.650, P = 0.067) in anti-Jo-1 positive patients. Furthermore, in patients with dermatomyositis, serum resistin levels significantly correlated with MYOACT (r = 0.667, P = 0.001), creatine kinase (r = 0.739, P = 0.001) and myoglobin levels (r = 0.791, P = 0.0003) and showed a trend towards correlation with CRP levels (r = 0.447, P = 0.067). Resistin expression in muscle tissue was significantly higher in patients with inflammatory myopathies compared to controls, and resistin induced the expression of interleukins (IL)-1β and IL-6 and monocyte chemoattractant protein (MCP)-1 in mononuclear cells but not in myocytes.

Conclusions

The results of this study indicate that higher levels of serum resistin are associated with inflammation, higher global disease activity index and muscle injury in patients with myositis-specific anti-Jo-1 antibody and patients with dermatomyositis. Furthermore, up-regulation of resistin in muscle tissue and resistin-induced synthesis of pro-inflammatory cytokines in mononuclear cells suggest a potential role for resistin in the pathogenesis of inflammatory myopathies.